CytoGenix Receives Re-Supply Order for synDNA™
News Jun 14, 2006
The current order for synDNA™ was placed after the initial batch of synDNA™ proved to be the preferred material for use in the manufacture of innovative products by the client.
"The CytoGenix synDNA™ technology is ideally suited for many of our clients when conventional plasmid DNA is too costly or difficult to produce," stated Michael Chambers, President and CEO of Aldevron.
"The first order of synDNA™ met and exceeded our expectations in terms of quality, cost, and turn-around time."
"The relationship between CytoGenix and Aldevron continues to be mutually beneficial," said Malcolm Skolnick, President and CEO of CytoGenix.
"We are delighted to service clients by utilizing our excess production capacity thereby generating revenue to fund our internal product development programs."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.